Do patients with cN0 oral squamous cell carcinoma benefit from elective neck dissection? A large-scale population-based study

医学 颈淋巴结清扫术 比例危险模型 口腔颌面外科 内科学 危险系数 肿瘤科 基底细胞 生存分析 子群分析 外科 置信区间
作者
Qiuyu Wu,Yuanhang Xia,Ling Qiu,Shuqiong Wen,Qunxing Li,Gao Xiang,Wen-Rong Jiang,Tao Wang,Ping Ji,Zhanpeng Ou
出处
期刊:BMC Oral Health [BioMed Central]
卷期号:24 (1)
标识
DOI:10.1186/s12903-023-03632-5
摘要

Abstract Background The neck management of clinical-nodal negative (cN0) oral squamous cell carcinoma (OSCC) remains controversial. Elective neck dissection (END) and observation are the main strategies, but it is still not clear who could benefit the most from END. The purpose of this study was to clarify the potential clinical factors that affect the therapeutic value of END and to explore the actual characteristics associated with benefit from END. Methods Patients with cN0 OSCC were identified in the SEER database from 2000 to 2019. 5-year Overall survival (OS) and disease-specific survival (DSS) were analyzed using the Kaplan‒Meier method, and the hazard ratios (HRs) for survival were estimated using the Cox regression model. Multiple subgroup analyses of DSS and OS among different factors, comparing END and No END, were performed. Results A total of 17,019 patients with cN0 OSCC were included. The basic survival analysis and Cox regression model showed that END increased the probability of 5-year DSS and OS and was an independent prognostic factor. However, among patients who underwent only primary tumor surgery, no significant differences were found between the END and No END groups in 5-year DSS ( P = 0. 585) and OS ( P = 0.465). Further subgroup analysis showed that primary sites and T stage, but not other factors, might influence the benefit of END. Significant differences were found for T1 ( P < 0.001 for OS) and T2 ( P = 0.001 for DSS and < 0.001 for OS) tongue squamous cell carcinoma (TSCC) but not for other primary tumor sites. Conclusion This large-scale retrospective population-based cohort study suggests that not all patients with cN0 OSCC could benefit from END. Patients with cN0 TSCC are recommended to undergo END, especially with early-stage tumors.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
xuxuxuuxuxux完成签到,获得积分10
刚刚
桐桐应助知名不具采纳,获得10
2秒前
俭朴的一曲完成签到,获得积分10
3秒前
斯文败类应助读者采纳,获得10
3秒前
柯一一应助久久采纳,获得10
3秒前
酷酷的豆芽完成签到,获得积分20
4秒前
111发布了新的文献求助10
4秒前
5秒前
coolkid应助Fx采纳,获得10
5秒前
充电宝应助KD采纳,获得10
6秒前
小蘑菇应助得灵梦采纳,获得10
7秒前
7秒前
三岁半完成签到 ,获得积分10
8秒前
刘丹丹发布了新的文献求助10
8秒前
黑黑完成签到,获得积分20
9秒前
量子星尘发布了新的文献求助10
9秒前
感动代双发布了新的文献求助10
9秒前
一种信仰发布了新的文献求助10
10秒前
斯文败类应助chenlc971125采纳,获得10
11秒前
Linda完成签到,获得积分20
12秒前
黑黑发布了新的文献求助10
12秒前
南烛发布了新的文献求助10
12秒前
清宁亦无拘完成签到 ,获得积分10
12秒前
13秒前
13秒前
tdtk发布了新的文献求助10
14秒前
CAOHOU应助天音玄鸟采纳,获得10
14秒前
16秒前
EtanJ完成签到,获得积分10
17秒前
雪白的千雁完成签到 ,获得积分10
17秒前
wanci应助bzqqqqq采纳,获得10
17秒前
17秒前
18秒前
tmxx发布了新的文献求助10
18秒前
18秒前
20秒前
DentistRui发布了新的文献求助10
20秒前
20秒前
李爱国应助科研通管家采纳,获得10
20秒前
estrella发布了新的文献求助30
20秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 588
T/CIET 1202-2025 可吸收再生氧化纤维素止血材料 500
Comparison of adverse drug reactions of heparin and its derivates in the European Economic Area based on data from EudraVigilance between 2017 and 2021 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3952993
求助须知:如何正确求助?哪些是违规求助? 3498423
关于积分的说明 11091766
捐赠科研通 3229049
什么是DOI,文献DOI怎么找? 1785199
邀请新用户注册赠送积分活动 869228
科研通“疑难数据库(出版商)”最低求助积分说明 801411